Statement of Changes in Beneficial Ownership (4)

Date : 02/15/2020 @ 6:04AM
Source : Edgar (US Regulatory)
Stock : Capricor Therapeutics Inc (CAPR)
Quote : 1.18  -0.02 (-1.67%) @ 9:21PM

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

DUNBAR GEORGE W JR
2. Issuer Name and Ticker or Trading Symbol

CAPRICOR THERAPEUTICS, INC. [ CAPR ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)

2/12/2020
(Street)

BEVERLY HILLS, CA 90211
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $1.39 2/12/2020  A   5250     (1)8/8/2029 Common Stock 5250  (2)5250 D  
Stock Option (Right to Buy) $1.39 2/12/2020  A   2800     (3)1/2/2028 Common Stock 2800  (2)2800 D  
Stock Option (Right to Buy) $1.39 2/12/2020  A   2606     (4)1/3/2027 Common Stock 2606  (2)2606 D  
Stock Option (Right to Buy) $1.39 2/12/2020  A   3000     (5)6/2/2026 Common Stock 3000  (2)3000 D  
Stock Option (Right to Buy) $1.39 2/12/2020  A   750     (5)3/3/2025 Common Stock 750  (2)750 D  
Stock Option (Right to Buy) $1.39 2/12/2020  A   1401     (5)3/6/2023 Common Stock 1401  (2)1401 D  
Stock Option (Right to Buy) $1.39 2/12/2020  A   15455     (5)4/27/2022 Common Stock 15455  (2)15455 D  
Stock Option (Right to Buy) $3.25 2/12/2020  D     5250   (1)8/8/2029 Common Stock 5250  (2)0 D  
Stock Option (Right to Buy) $15.70 2/12/2020  D     2800   (3)1/2/2028 Common Stock 2800  (2)0 D  
Stock Option (Right to Buy) $25.50 2/12/2020  D     2606   (4)1/3/2027 Common Stock 2606  (2)0 D  
Stock Option (Right to Buy) $31.20 2/12/2020  D     3000   (5)6/2/2026 Common Stock 3000  (2)0 D  
Stock Option (Right to Buy) $57.80 2/12/2020  D     750   (5)3/3/2025 Common Stock 750  (2)0 D  
Stock Option (Right to Buy) $3.70 2/12/2020  D     1401   (5)3/6/2023 Common Stock 1401  (2)0 D  
Stock Option (Right to Buy) $3.70 2/12/2020  D     15455   (5)4/27/2022 Common Stock 15455  (2)0 D  

Explanation of Responses:
(1) 3,000 of the shares were vested on the date of grant. The remaining 2,250 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
(2) The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.
(3) 1,050 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 1,750 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
(4) 856 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 1,750 shares will vest 1/12th on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
(5) The stock option award is fully vested and exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
DUNBAR GEORGE W JR
C/O CAPRICOR THERAPEUTICS, INC.
8840 WILSHIRE BLVD., 2ND FLOOR
BEVERLY HILLS, CA 90211
X



Signatures
/s/ Linda Marban, as Attorney-in-Fact2/14/2020
**Signature of Reporting PersonDate

Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart

1 Year : From Feb 2019 to Feb 2020

Click Here for more Capricor Therapeutics Charts.

Capricor Therapeutics (NASDAQ:CAPR)
Intraday Stock Chart

Today : Friday 28 February 2020

Click Here for more Capricor Therapeutics Charts.

Latest CAPR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.